

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application No. 09/898,234
 Filing Date: 7-3-01
 First Named Inventor Hauptmann et al.,
 Group Art Unit
 Examiner Name
 Attorney Docket No. 98,385-I

Sheet

5

of

9

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

- Evans, "The steroid and thyroid hormone receptor superfamily," *Science* 240:889-95 (1988).
- 82 Frohman et al., "Rapid production of full-length cDNAs from rare transcripts: amplification using a single gene-specific oligonucleotide primer," *Proc. Natl. Acad. Sci. U. S. A.* 85:8998-9002 (1988).
- 83 Gatanaga et al., "Purification and characterization of an inhibitor (soluble tumor necrosis factor receptor) for tumor necrosis factor and lymphotoxin..., *Proc. Natl. Acad. Sci. USA* 87:8781-8784 (1990).
- 84 Goodson et al., "Site-Directed Pegylation of Recombinant Interleukin-2 At Its Glycosylation Site," *BioTechnology* 8:343-346 (1990).
- 85 Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 murine receptors for tumor necrosis factor," *Mol. Cell. Biol.* 11:3020-26 (1991).
- 86 Gray et al., "Cloning of human tumor necrosis factor (TNF) receptor cDNA and expression of recombinant soluble TNF-binding protein," *Proc. Natl. Acad. Sci. U. S. A.* 87:7380-84 (1990).
- 87 Grizzard et al., "Affinity-labeled somatomedin-C receptors and binding proteins from the human fetus," *J. Clin. Endocrinol. Metab.* 58:535-43 (1984).
- 88 Hale et al., "Cytokines and Their Receptors: From Clonal to Clinical Investigation, Demonstration of In Vitro and In Vivo Efficacy of Two Biologically Active Human Soluble TNF Receptors Expressed in E. Coli," *J. Cell Biochem. Suppl.* 15F:113(1991)
- 89 Hass et al., "Characterization of specific high affinity receptors for human tumor necrosis factor on mouse fibroblasts," *J. Biol. Chem.* 260:12214-18 (1985).
- 90 Hatakeyama et al., "Interleukin-2 receptor beta chain gene: generation of three receptor forms by cloned human alpha and beta chain cDNA's," *Science* 244:551-56 (1989).
- 91 Hauser et al., "Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6," *Neurology* 40:1735-39 (1990).
- 92 Heller et al., "Complimentary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor," *Proc. Natl. Acad. Sci. USA* Vol. 87, pp. 6151-6155, August 1990.
- 93 Himmler et al., "Molecular cloning and expression of human and rat tumor necrosis factor receptor chain (p60) and its soluble derivative, tumor necrosis factor-binding protein," *DNA Cell Biol.* 9:705-15 (1990).
- 94 Hofman et al., "Tumor necrosis factor identified in multiple sclerosis brain," *J. Exp. Med.* 170:607-12 (1989).
- 95 Hohmann, H.P. et al., *J. Biol. Chem.* 264:14927-14934, *Sept. 1989*
- 96 Israel et al. "Binding of Human TNF-alpha to High-Affinity Cell Surface Receptors: Effect of IFN," *Immunol. Lett.* 12:217-224(1986).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

Cileen B. O'Hara

1/21/03

Substitute for form 1449A/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application No. 09/898,234

Filing Date: 7-3-01

First Named Inventor Hauptmann et al.,

Group Art Unit

Examiner Name

Attorney Docket No. 98,385-1

Sheet

of

9

OTHER DOCUMENTS (Including Prior Art, Title, Date, Pertinent Pages, Etc).

- 127 Seckinger et al., "A Human Inhibitor of Tumor Necrosis Factor Alpha," J. Exp. Med. 167:1511-1516, 1988
- 128 Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1 and B But Not Tumor Necrosis Factor a," J. Immunol. 139(5):1541-1545(1987).
- 129 Seckinger et al., "A Urine Inhibitor of Interleukin 1 Activity Affects Both Interleukin 1 and B But Not Tumor Necrosis Factor a," J. Immunol. 139(5):1446-1549(1987)
- 130 Selmaj et al., "Prevention of Chr-eae with Soluble TNF Receptor P55," J. Neuroimmunology 54(2) p196 1994
- 131 Selmaj and Raine, "Anti-Tumor Necrosis Factor Therapy Abrogates Autoimmune Demyelination, Annals of Neurology Vol 30 No 5 November 1991.
- 132 Shimizu et al., PNAS USA, 80:2112-2116 (1983).
- 133 Smith et al., "A Receptor for Tumor Necrosis Factor Defines an Unusual Family Cellular and Viral Proteins, Reports, 1019-1023. Science, May 1990.
- ~~134 Smith et al., Science 248:1019-1023(1990)~~
- 135 Socher et al., "Antibodies against amino acids 1-15 of tumor necrosis factor block its binding to cell-surface receptor," Proc. Natl. Acad. Sci. U. S. A. 84:8829-33 (1987).
- 136 Spinaz et al., "Induction of plasma inhibitors of interleukin 1 and TNF-alpha activity by endotoxin administration to normal humans," Am. J. Physiol. 259(5 Pt 2):R993-7 (1990).
- 137 Stauber and Aggarwal, "Characterization and affinity cross-linking of receptors for human recombinant lymphotoxin (tumor necrosis factor-beta) on a human histiocytic lymphoma cell line, U-937," J. Biol. Chem. 264:3573-76 (1989).
- 138 Stauber, G. et al., J. Biol. Chem. 263(35):19098-19104. Dec. 1988
- 139 Suffys et al., "Involvement of a serine protease in tumour-necrosis-factor-mediated cytotoxicity," Eur. J. Biochem. 178:257-65 (1988).
- 140 Suggs et al., "Use of synthetic oligonucleotides as hybridization probes: isolation of cloned cDNA sequences for human beta 2-microglobulin," Proc. Natl. Acad. Sci. U. S. A. 78:6613-17 (1981).
- 141 The Cytokine Factsbook pp. 244-46 (Callard, ed., Academic Press, 1994).
- 142 Tracey et al., "Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation," J. Exp. Med. 167:1211-27 (1988).
- 143 Tracey et al., "Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. Cachectin/tumor necrosis factor-secreting tumor in skeletal muscle induces chronic cachexia, while implantation in brain induces predominantly acute anorexia," J. Clin. Invest. 86:2014-24 (1990).

Chen B.O/Hara 1/21/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

Attorney Docket No.

98-385-1

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear
		Number	Kind Code ² (if known)			
EPA		6,294,352	B1	Hauptmann et al.	09-25-2001	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines Where Relevant Passages or Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
EPA	1	DE	3913101.7	A1	Boehringer Ingelheim International GmbH	04/29/1989		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
EPA	✓	HELLER <i>et al.</i> , "Complementary DNA cloning of a receptor for tumor necrosis factor and demonstration of a shed form of the receptor", <i>Proc. Natl. Acad. Sci.</i> 87: 6151-55 (1990).	
	✓	PEPPEL <i>et al.</i> , "A Tumor Necrosis Factor (TNF) Receptor-IgG Heavy Chain Chimeric Protein as a Bivalent Antagonist of TNF Activity," <i>J. Exp. Med.</i> 174:1483-89 (1991).	
	✓	POWELL <i>et al.</i> , "Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein specific T-cell clones correlates with encephalitogenicity," <i>Int. Immunol.</i> 2:539-44 (1990).	
	✓	POWELL <i>et al.</i> , "The Role of Lymphotoxin and TNF in Demyelinating Diseases of the CNS," <i>Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine.</i> pgs 355-69. 1992	
	✓	RHEIN <i>et al.</i> , "Another Sepsis Drug Down-Immunex TNF Receptor," <i>Biotechnology Newswatch</i> , pg. 1,3 (Monday, October 4, 1991)	
	✓	VILCEK <i>et al.</i> , "Tumor Necrosis Factor: Receptor Binding and Mitogenic Action in Fibroblasts," <i>J. Cell. Physiol.</i> 5:57-61 (1987).	
✓	✓	SELMAJ <i>et al.</i> , "Tumor Necrosis Factor Mediates Myelin and Oligodendrocyte Damage In Vitro," <i>Ann. Neurol.</i> 23(4):339-46 (1988).	

Examiner Signature

Eileen B. O'Hara

Date Considered

10/13/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC. 20231

File Copy